Key clinical point: The costs associated with migraine care increase with the number of treatment failures.
Major finding: Total per-patient medical cost per year for office visits was $35,392 among patients with three or more treatment failures.
Study details: A review of IBM MarketScan data for patients with a new diagnosis of migraine between Jan. 1, 2011, and June 30, 2015.
Disclosures: The study was supported by Novartis Pharma, one of the developers of erenumab. Dr. Newman has received compensation from Allergan, Alder, Amgen, Biohaven, Novartis, Teva, Supernus, and Theranica.
Newman L et al. AAN 2020, Abstract S47.009.